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It has been shown that growth hormone-releasing hormone (GHRH)
reduces cardiomyocyte (CM) apoptosis, prevents ischemia/reperfu-
sion injury, and improves cardiac function in ischemic rat hearts.
However, it is still not known whether GHRH would be beneficial for
life-threatening pathological conditions, like cardiac hypertrophy
and heart failure (HF). Thus, we tested the myocardial therapeutic
potential of GHRH stimulation in vitro and in vivo, using GHRH or its
agonistic analog MR-409. We show that in vitro, GHRH(1-44)NH2 at-
tenuates phenylephrine-induced hypertrophy in H9c2 cardiac cells,
adult rat ventricular myocytes, and human induced pluripotent stem
cell-derived CMs, decreasing expression of hypertrophic genes and
regulating hypertrophic pathways. Underlying mechanisms included
blockade of Gq signaling and its downstream components phospho-
lipase Cβ, protein kinase Ce, calcineurin, and phospholamban. The
receptor-dependent effects of GHRH also involved activation of Gαs
and cAMP/PKA, and inhibition of increase in exchange protein di-
rectly activated by cAMP1 (Epac1). In vivo, MR-409 mitigated cardiac
hypertrophy in mice subjected to transverse aortic constriction and
improved cardiac function. Moreover, CMs isolated from transverse
aortic constriction mice treated with MR-409 showed improved con-
tractility and reversal of sarcolemmal structure. Overall, these results
identify GHRH as an antihypertrophic regulator, underlying its ther-
apeutic potential for HF, and suggest possible beneficial use of its
analogs for treatment of pathological cardiac hypertrophy.
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Cardiac hypertrophy is initially an adaptive response of theheart to pathophysiologic stimuli, in an attempt to counter-
balance ventricular wall stress and preserve cardiac function.
However, sustained hypertrophy in response to cardiac insults,
such as hypertension or myocardial infarction (MI), can even-
tually lead to arrhythmias, dilated cardiomyopathy, and heart
failure (HF), leading causes of cardiac morbidity and mortality
(1). At a cellular level, pathological hypertrophy is characterized
by myocyte enlargement and increased protein synthesis, gene-
expression reprogramming, and modifications in the sarcomere
organization (1, 2). Many pathways are implicated in the trans-
duction of hypertrophic signals, and the initiating stimuli include
biomechanical stress and neurohumoral factors, associated with the
release of hormones, cytokines, and growth factors by cardiomyocytes
(CMs) themselves (2–4). Thus, a major therapeutic strategy in HF is
the use of pharmacologic agents aimed at limiting the progression of
cardiac hypertrophy. In fact, angiotensin-converting enzyme in-
hibitors, angiotensin receptor blockers, or β-adrenergic blockers
impact on cardiac function by acting on hypertrophy, together with
other effects, including those on inotropism (2). These drugs inhibit
neuroendocrine signaling, acting also on mechanisms responsible for
myocyte growth, cardiac hypertrophy, and HF; however, HF pro-
gression is still unavoidable, with a mortality of 50% within 5 y in
advanced stages (2, 3). Therefore, identifying new therapeutic
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targets to prevent or reverse cardiac hypertrophy may have an
impact on survival.
In addition to regulating the release of pituitary growth hormone
(GH), GH-releasing hormone (GHRH) exerts many peripheral
effects (5, 6), displaying autocrine and paracrine actions and reg-
ulating the survival and proliferation of different cell types. Ac-
cordingly, the expression of both GHRH and GHRH receptors has
been demonstrated in extrapituitary sites (5), including CMs (7–9),
skeletal myoblasts, and myotubes (10). We have recently demon-
strated the antiapoptotic action of GHRH in H9c2 cardiac cells and
adult rat ventricular myocytes (ARVMs), through signaling medi-
ated by the GHRH receptor (GHRH-R) and activation of cAMP/
protein kinase A (PKA) (7). GHRH also improved heart function
and reduced MI in isolated rat hearts subjected to ischemia/
reperfusion (7, 11). Furthermore, synthetic GHRH analogs, with
greater activity and metabolic stability compared with native
GHRH, were found to promote cardiac repair, improve cardiac
function, and reverse ventricular remodeling in rat models of is-
chemic injury (8, 12, 13), and to reduce MI in swine with ischemic
cardiomyopathy (14). Recently, highly potent new GHRH analogs,
such as MR-356 and MR-409, have been shown in vitro to reduce
calcium influx and promote the survival of H9c2 cardiac cells, and
in vivo to reduce rat MI and inflammatory response (9).
These findings suggest that GHRH and its analogs could be
useful for therapy of cardiovascular diseases; however, the role
of GHRH in cardiac hypertrophy and HF in vivo has not been
investigated to date. Hence, in the present study we tested the
hypothesis that GHRH would attenuate cardiac hypertrophy.
The role of GHRH was assessed in different in vitro models of
phenylephrine (PE)-induced hypertrophy, along with the mech-
anisms involved in these effects. The results obtained from the
in vitro experiments were further validated in vivo by in-
vestigating the therapeutic action of the GHRH analog MR-
409 in a mouse model of pressure overload hypertrophy and HF
induced by transverse aortic constriction (TAC).
Results
GHRH Attenuates PE-Induced Hypertrophy in Cardiac Cells. To test
the impact of GHRH on hypertrophy, we initially used H9c2
cardiac cells that possess biochemical and electrophysiological
characteristics of CMs and similar hypertrophic responses (15,
16). The cells were cultured for 24 h with GHRH at a concen-
tration of 0.5 μM, previously observed to be the most protective
against apoptosis (7), alone or with PE (10 and 50 μM). PE, but not
GHRH, increased cell surface area, whereas pretreatment with
GHRH blocked this effect (Fig. S1A). GHRH also lowered the
expression of hypertrophic markers NPPA and MYH7, encoding
atrial natriuretic peptide and β-myosin heavy chain (β-MHC), re-
spectively, both up-regulated by PE (Fig. S1 B and C).
The GHRH-R antagonist JV-1-36, used at 50 nM, in line with
our previous studies (7), had no effect alone; however, it blocked
the antihypertrophic action of GHRH in PE-treated cells, sug-
gesting receptor-mediated mechanisms (Fig. S1 D and E).
GHRH Inhibits Gq Signaling. Activation of Gq protein by receptors,
such as α1-adrenercic receptors (α1-AR), promotes cardiac hy-
pertrophy in vivo and in isolated CMs (4). Hence, we tested the
capacity of GHRH to inhibit PE-induced Gq/phospholipase Cβ
(PLCβ) signaling. The PLC inhibitor U-73122 blocked the in-
crease in NPPA and MYH7 mRNA in PE-treated H9c2 cells,
whereas GHRH maintained its antihypertrophic action, sug-
gesting Gq mediated signaling only for PE (Fig. S2 A and B).
Although both GHRH and PE alone increased PLCβ protein,
their coadministration reduced PLCβ to control levels (Fig. S2C).
Similar results were obtained for phosphorylation of PKCe at Ser729
and for calcineurin, downstream targets of PLCβ (Fig. S2 D and
E). GHRH also counteracted the effect of PE on phosphorylation
of phospholamban (PLN) at Thr17, dependent on Ca2+/calmodulin-
dependent protein kinase II (CaMKII) (Fig. S2F).
GHRH Activates Adenylyl Cyclase/cAMP/PKA. It is known that
GHRH-R activates Gαs and adenylyl cyclase (AC)/cAMP/PKA
(5–7); moreover, β-AR signaling, mediated by cAMP/PKA, may
antagonize α1-AR and CM hypertrophy (17), whereas α1-AR
agonists also stimulate β-AR signaling (18, 19). Here, both GHRH
and PE alone increased PKA activity; however, this effect was
potentiated in cardiac cells costimulated with PE and GHRH.
Moreover, the PKA activator, N6-benzoyladenosine-3′-5′-cAMP
(6-Bnz-cAMP), and the AC activator forskolin (FSK) increased,
whereas the PKA inhibitor, KT5720, reduced PKA activity (Fig.
S3A). Accordingly, GHRH also promoted the PKA-dependent
phosphorylation of PLN at Ser16, whereas PE had no effect,
both alone and in combination with GHRH (Fig. S3B). FSK
inhibited the increase in NPPA and MYH7 by PE, but potentiated
the antihypertrophic effect of GHRH (Fig. S3 C and D); this, in
turn, was inhibited by KT5720, which had no effect on PE alone
(Fig. S3 E and F). Thus, the antihypertrophic action of GHRH
involves AC/cAMP/PKA signaling and, although elevated by PE,
PKA is not implicated in the hypertrophic effect of PE.
GHRH Counteracts PE-Induced Increase in Epac1. Increase in ex-
change protein directly activated by cAMP1 (Epac1) is involved in
cardiac hypertrophy, HF, and arrhythmogenesis through β-ARs
signaling (20–23). Here, PE, but not GHRH, increased Epac1
mRNA in H9c2 cells, an effect abolished by GHRH (Fig. S4A).
The PKA activator 6-Bnz-cAMP, ineffective on Epac1 (24),
blocked PE-induced increase in Epac1 and potentiated the in-
hibitory action of GHRH on Epac1 reduction (Fig. S4B). Both the
inhibitor of Epac1, ESI-09, with no activity on PKA (22), and the
β1-AR antagonist metoprolol, blocked the PE-induced elevation of
Epac1, NPPA, and MYH7, with no effect on the antihypertrophic
action of GHRH (Fig. S4 C–H). These results suggest that GHRH
blocks the increase in Epac1 and counteracts the hypertrophic
action of PE through mechanisms mediated by cAMP and PKA.
GHRH Attenuates Hypertrophy in ARVMs and Human Induced Pluripotent
Stem Cell-Derived CMs. The antihypertrophic effect of GHRH was
then tested in ARVMs and human induced pluripotent stem cell-
derived CMs (iPSC-CMs). ARVMs, cultured for 24 h with PE,
showed increased cell surface area. This effect was attenuated by
pretreatment with GHRH (Fig. 1A), which also reduced the in-
crease in NPPA and MYH7 mRNA (Fig. 1 B and C). Moreover,
GHRH counteracted the up-regulation in Epac1 by PE, while
having no effect alone (Fig. 1D). Human iPSC-CMs showed ex-
pression for pituitary GHRH-R and GHRH, but not for the re-
ceptor splice variant SV1 (Fig. 1E). Treatment with PE for 24 h
increased mRNA levels of NPPA, NPPB (encoding brain natri-
uretic peptide), and Epac1; these effects were abolished by
cotreatment with GHRH (Fig. 1 F–H).
MR-409 Improves Cardiac Function and Remodeling in Pressure
Overload-Induced HF. The effect of the synthetic agonistic analog
of human GHRH, MR-409, was tested in the TAC-induced
pressure overload model of HF. At 4-wk, TAC mice displayed a
significant depression of cardiac function, as evaluated by
echocardiographic parameters [i.e., ejection fraction and frac-
tional shortening (FS)]. MR-409 was given 2 wk after TAC, when
mice had developed left ventricular hypertrophy and showed a
decrease in cardiac function (Fig. 2). Four weeks after TAC, the
decrease of FS, the progressive left ventricular dilation, and the
transition from concentric to dilated hypertrophy in left ventri-
cles were hindered by the treatment with MR-409 (Fig. 2B and
Table 1). At 4-wk after TAC, H&E staining showed that the
hearts from MR-409–treated mice were smaller compared with
those of TAC control (Fig. 3A, Upper). Cross-sectional area
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analysis in isolated CMs revealed a reversal in myocyte en-
largement in TAC mice treated with MR-409 compared with
untreated (Fig. 3A, Lower, and 3B), whereas expression of
markers of fibrosis and apoptosis was unchanged (Fig. S5 A–E).
mRNA for NPPA and NPPB was reduced in CMs of TAC mice
treated with MR-409, whereas MYH6 (encoding α-MHC) and
Acta1 (encoding skeletal α-actin) levels were unchanged (Fig.
3C). MR-409 also counteracted the effect of TAC on increase in
Epac1, and up-regulated the expression of sarco/endoplasmic
reticulum Ca2+ ATPase 2a (SERCA2a), that was reduced by
TAC (Fig. 3D). The serum levels of GH and IGF-I, measured at
the end of 4-wk TAC, were unchanged in both sham- and TAC-
operated mice treated with MR-409 (Fig. S5 F and G).
MR-409 Promotes the Normalization of Contractile Responses in TAC
CMs ex Vivo. A feature of the reverse-remodeled heart is the
recovery of contractile responses in isolated CMs, which are
blunted during HF (25). Thus, the effect of MR-409 was next
studied on the contractility of CMs isolated from TAC mice.
Chronic treatment with MR-409 improved both cell shortening
at all stimulation frequencies (Fig. S6A) and velocity of cell re-
laxation (Fig. S6B). Similarly, the magnitude of calcium tran-
sients ameliorated the rising phase (calculated as percentage
from baseline-to-peak) increased for all stimulation frequencies,
suggesting an improved release of calcium ions from the sarco-
plasmic reticulum (Fig. S6C). Consequently, the “falling phase”0
1
2
*
#
Ep
ac
1/
18
S 
rR
N
A
(fo
ld
 c
ha
ng
e)
c G PE PE
+G
A
PEC
el
l s
ur
fa
ce
 a
re
a 
(fo
ld
 c
ha
ng
e)
0
1
2
**
#
c G PE
+G
N
PP
A
/1
8S
 rR
N
A
 (f
ol
d 
ch
an
ge
)
0
1
2
3
**
##
B
PEc G PE
+G
M
YH
7/
18
S 
rR
N
A
(fo
ld
 c
ha
ng
e)
0
1
2
3 **
#
C
PEc G PE
+G
D
H
0
0.5
1
1.5
2
2.5
c G PE PE
+G
Ep
ac
1/
18
S 
rR
N
A
 (f
ol
d 
ch
an
ge
)
**
##
0
2
4
6
8
10
N
PP
A
/1
8S
 rR
N
A
 (f
ol
d 
ch
an
ge
)
**
#
c G PE PE
+G
F
0
1
2
3
4
5
6
N
PP
B
/1
8S
 rR
N
A
 (f
ol
d 
ch
an
ge
)
##
*
c G PE PE
+G
G
ns
ns
E
GHRH-R191 bp
- + hiPSC-
CMs
β-actin230 bp
GHRH175 bp
SV1563 bp
Adult rat ventricular myocytes (ARVMs)
iPSC-derived cardiomyocytes (iPSC-CMs)
Fig. 1. Antihypertrophic effect of GHRH in ARVMs and human iPSC-CMs. Se-
rum-starved ARVMs were treated with GHRH (0.5 μM) and PE (10 μM) for 24 h,
alone or with GHRH for 40 min, then with PE for 24 h. (A) Cell surface area
measured on α-actinin–stained cells. The relative area, normalized to the control,
was analyzed in at least 50 cells for each condition in three different fields.
(B–D) Real-time PCR for NPPA, MYH7, and Epac1 normalized to 18S rRNA. For
A–D, results, expressed as fold-change of control (c), are mean ± SEM *P < 0.05 and
**P < 0.01 vs. c; #P < 0.05 and ##P < 0.01 vs. PE; n = 3. (E) Representative RT-PCR
showing mRNA for GHRH-R, SV1, and GHRH in human iPSC-CMs. Buffer alone
was used as negative control (−). LNCaP human prostate cancer cells were used
as positive control (+) and β-actin as internal control. NPPA (F), NPPB (G), and
Epac1 (H) mRNA assessed by real-time PCR in cells treated for 24 h with 0.5 μM
GHRH and 100 μM PE, alone or in combination. Results, normalized to 18S
rRNA, are expressed as fold-change of control (c) and aremean± SEM*P< 0.05 and
**P < 0.01 vs. c; #P < 0.05 and ##P < 0.01 vs. PE; ns, not significant vs. c; n = 3.
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Fig. 2. Antihypertrophic effect of MR-409 in vivo. After 14 d, mice subjected to
sham operation or TAC underwent echocardiography analysis for heart func-
tion and pressure gradient. Only micewith gradients between 60 and 90mmHg
were included in the experiment. Two weeks (wk) after the operation, mice
were subcutaneously injected with MR-409 (500 μg/kg/d for 14 d) or vehicle.
(A) Representative M-mode left ventricular echocardiographic recording at
baseline, 2 wk post-TAC, 4 wk post-TAC, and 4 wk post-TAC with MR-409.
(B) Echocardiographic data: EF%, percent ejection fraction and FS (%), percent
fractional shortening, as parameters of left ventricle contractile function; RWT,
relative wall thickness. Arrows indicate the time of MR-409 administration
(from 2 to 4 wk after TAC). Results are mean ± SEM ***P < 0.001 vs. TAC Basal;
##P < 0.01 and ###P < 0.001 vs. TAC MR-409 basal; §§P < 0.01 and §§§P < 0.001 vs.
TAC control 2 wk; ††P < 0.01 and †††P < 0.001; ns, not significant (Sham, n = 5;
Sham MR, n = 5; TAC, n = 8; Tac MR, n = 9).
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required more time-to-reuptake calcium ions and store them in
the sarcoplasmic reticulum (calculated as percentage from peak
to baseline at the 90% of time) at 1, 2, and 3 Hz (Fig. S6D).
Overall, CMs exposed to MR-409 denoted a decrease in the time
of mechanical relaxation but an increase in the time of calcium
reuptake (Fig. S6 B and D).
In HF, CMs show a typical alteration in morphology and orga-
nization of cell membrane transverse tubules (T-tubules) (26) that
can be studied by hopping probe scanning ion-conductance mi-
croscopy (HPICM), for topographical evaluation of cell membrane
organization at nanoscale resolution (27, 28). HPICM revealed a
recovery of the alternating z-groove and crest morphology on the
surface of CMs from TAC mice treated with MR-409, compared
with CMs from TAC control mice, which showed less-striated
membrane topography. An increase, from 0.43 ± 0.02 to 0.57 ±
0.05, in the z-groove index was observed in CMs from TAC MR-
409 compared with TAC control mice (Fig. S7).
Discussion
Our results demonstrate that GHRH attenuates cardiac hyper-
trophy under pathological conditions. Indeed, GHRH inhibited
PE-induced hypertrophy in H9c2 cardiac cells, as well as in
ARVMs and human iPSC-CMs, while its analog, MR-409, re-
capitulates the same rescuing in vivo.
Of note, although our groups have recently demonstrated the
cardioprotective role of GHRH, both in vitro and in vivo (7–9, 11–
14), the potential protective effect of the hormone in the context of
HF has not been previously investigated. We found that in vitro,
GHRH reduced the increase in expression of fetal genes by PE,
which are classically associated with the development of pathological,
but not physiological hypertrophy (29). The antihypertrophic action
of GHRH, dependent on activation of GHRH-R, also included
blockade of Gq signaling, induced by PE. In fact, GHRH abolished
the increase in PLCβ expression and phosphorylation of PKCe by
PE, as well as elevation of calcineurin, and inhibited the CaMKII-
dependent phosphorylation of PLN at Thr17. Moreover, although
GHRH alone increased PLCβ signaling, its antihypertrophic action
was not affected by the PLCβ inhibitor, suggesting that Gq signaling
is implicated in other effects of the hormone.
In addition to Gq, our results show that the antihypertrophic
action of GHRH involved its canonical pathway, namely the
GHRH-R–dependent Gαs/cAMP/PKA (5, 7, 10). GHRH enhanced
PKA activity, an effect also observed with PE, in line with studies
showing that high concentrations of PE may activate β-AR signaling
in CMs (18, 19). Interestingly, the combination of GHRH and PE
further increased PKA activity, suggesting that PKA is implicated in
the antihypertrophic activity of GHRH. Accordingly, β-AR–in-
duced elevation of cAMP/PKA was previously shown to reduce the
fetal gene response to α1-AR agonists, including PE, in CMs (17).
Moreover, our results show that GHRH, but not PE, promoted the
PKA-dependent phosphorylation of PLN at Ser16. In line with
these findings, activation of cAMP/PKA by FSK blocked the hy-
pertrophic effect of PE, but potentiated the antihypertrophic action
of GHRH. Conversely, inhibition of PKA reduced the anti-
hypertrophic effect of GHRH, while being ineffective on PE, in-
dicating a PKA-mediated effect for GHRH, but not for PE.
To further clarify these mechanisms, we focused on Epac, a
direct PKA-independent target of cAMP and a mediator of
cardiac hypertrophy, HF, and arrhythmogenesis (20–23), whose
expression of the main cardiac isoform, Epac1, has been dem-
onstrated in H9c2 cells as well (20). Epac1 induces hypertrophy
in vitro and in vivo through mechanisms mediated by the PKA-
independent phosphorylation of PLN on Thr17, as well as Ca2+
release, activation of PLCe/PKCe/CaMKII signaling (22, 30),
Table 1. Echocardiographic analysis at basal, 2-wk, and 4-wk Sham and TAC mice treated with MR-409
Basal 2 wk 4 wk
Parameter Sham Sham MR TAC control TAC MR Sham Sham MR TAC control TAC MR Sham Sham MR TAC control TAC MR
BW, g 25.6 ± 2.1 25.8 ± 1.095 25.9 ± 2.2 26.4 ± 2.1 24.7 ± 2.6 26.6 ± 1.14 26.1 ± 2.0 26.6 ± 1.14 25.4 ± 2.9 28.2 ± 1.1 26.1 ± 1.7 27.1 ± 2.0
HR M-mode,
bpm
601.8 ± 17.6 588 ± 30.34 629.3 ± 158.3 593.6 ± 42.3 597.2 ± 53.7 588.8 ± 30.34 577.6 ± 55.8 523.0 ± 138.0 606.6 ± 46.9 627.2 ± 35.2 560.0 ± 24.6 630.1 ± 21.4†††
LVIDd, mm 3.3 ± 0.1 3.312 ± 0.233 3.4 ± 0.1 3.3 ± 0.2 3.22 ± 0.07 3.312 ± 0.23 3.67 ± 0.28** 3.54 ± 0.13 3.3 ± 0.2 3.296 ± 0.14 4.1 ± 0.3*** 3.7 ± 0.2†††
LVIDs, mm 2.0 ± 0.1 2.092 ± 0.225 2.0 ± 0.1 2.1 ± 0.2 1.95 ± 0.04 2.058 ± 0.219 2.49 ± 0.27*** 2.43 ± 0.15 2.0 ± 0.2 1.992 ± 0.07 3.0 ± 0.4*** 2.4 ± 0.3†††
IVSd, mm 0.9 ± 0.1 0.854 ± 0.053 0.9 ± 0.0 0.9 ± 0.0 0.8 ± 0.0 0.824 ± 0.05 1.0 ± 0.0** 1.0 ± 0.1 0.8 ± 0.0 0.87 ± 0.07 1.02 ± 0.07*** 1.02 ± 0.06
IVSs, mm 1.3 ± 0.1 1.232 ± 0.072 1.2 ± 0.1 1.3 ± 0.1 1.2 ± 0.0 1.21 ± 0.053 1.3 ± 0.1*** 1.3 ± 0.1 1.26 ± 0.06 1.222 ± 0.03 1.39 ± 0.06*** 1.40 ± 0.04
PWTd, mm 0.8 ± 0.0 0.858 ± 0.08 0.9 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.834 ± 0.053 1.0 ± 0.1** 1.0 ± 0.1 0.82 ± 0.10 0.862 ± 0.01 1.01 ± 0.08** 1.02 ± 0.09
PWTs, mm 1.2 ± 0.1 1.218 ± 0.036 1.2 ± 0.1 1.2 ± 0.0 1.2 ± 0.0 1.276 ± 0.043 1.4 ± 0.1*** 1.4 ± 0.0 1.26 ± 0.04 1.256 ± 0.06 1.38 ± 0.13*** 1.47 ± 0.07
Statistical significance was measured by two-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Basal TAC control; †††P < 0.001 vs. 4 wk TAC control. bpm, beats per minute; BW, body weight; HR, heart rate; IVSDd,
interventricular septal end diastole; IVSDs, interventricular septal end systole; LVIDd, left ventricular internal diameter end diastole; LVIDs, left ventricular internal diameter end systole; MR, MR-409; PWTd, posterior wall
thickness in end diastole; PWTs, posterior wall thickness in end systole. (Sham, n = 5; Sham MR, n = 5; TAC, n = 8; TAC MR, n = 9.)
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Fig. 3. Histological analysis and hypertrophic sig-
naling in TAC mice treated with MR-409. (A) Repre-
sentative mouse heart sections (Upper) and CM cross-
sectional area (Lower) 4 wk after TAC (Left, TAC
control) or TAC with MR-409 (Right) (H&E staining).
(B) Cell size of single adult CMs from TAC Control
and TAC MR-409 mice at 4-wk after TAC (n = 250,
three mice per group). (C) Expression of the indicated
genes in CMs from TAC MR-409 and TAC control mice
(4-wk). Results, normalized to 18S rRNA, are presented
as fold-change vs. TAC control (n = 3 mice per group)
and are mean ± SEM *P < 0.05. (D) Representative
Western blot for Epac1 and SERCA2a in left ventricles
from TAC mice treated with MR-409. Results, nor-
malized to GAPDH and expressed as percent of Sham,
are mean ± SEM *P < 0.05 vs. Sham; #P < 0.05; n = 5.
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and elevation of calcineurin and NFAT (21–23). We found that
PE increased Epac1 mRNA, an effect abolished by GHRH.
Moreover, the PKA activator 6-Bnz-cAMP blocked the increase
in Epac1 by PE and potentiated the inhibitory effect of GHRH,
consistent with the involvement of PKA in the antihypertrophic
action of the hormone. To the best of our knowledge, no studies
have previously demonstrated that an α1-AR agonist, such as PE,
up-regulates Epac1, which is typically activated by β-AR agonists
(23). Accordingly, the increase in Epac1 and the hypertrophic
effect of PE, but not the antihypertrophic action of GHRH, were
blocked by the Epac1 inhibitor ESI-09, and by the β1-AR an-
tagonist metoprolol. Collectively, these findings indicate that, in
addition to inhibiting Gq, GHRH blocks hypertrophy in CMs
through activation of receptor-mediated cAMP/PKA and in-
hibition of Epac1, suggesting cross-talk mechanisms between
α1- and β1-AR pathways (Fig. 4).
The antihypertrophic effect of GHRH was demonstrated also in
ARVMs and human iPSC-CMs, along with inhibition in Epac1 ex-
pression, suggesting a potential antihypertrophic action for GHRH
in the human heart. In fact, although displaying ultrastructural and
electrophysiological properties of immature CMs, human iPSC-CMs
are being intensively investigated because of their potential thera-
peutic applications, specifically in cardiac regeneration and patient-
specific cell therapy, representing promising tools for drug discovery
and the identification of novel therapeutic molecules (31).
In vivo experiments using the stable agonistic GHRH analog,
MR-409, confirmed the potent antihypertrophic properties of
GHRH in vitro. Interestingly, as the effect of GHRH(1-44)-NH2
could be reproduced with the analog of GHRH(1-29), MR-409
(13), the active cardioprotective sequence—that is, the part re-
sponsible for the cardiac effects—is likely contained in the first
29 amino acids of GHRH.
Importantly, treatment of TAC mice with MR-409 did not just
halt disease progression, but rather reversed dysregulated cardiac
function. MR-409 even counteracted the effect of TAC on in-
crease in Epac1 and on reduction of SERCA2a expression. Of
note, SERCA2a plays an essential role in the contraction and
relaxation of cardiac muscle and SERCA2a expression has been
shown to be reduced in left hypertrophic ventricles (32). More-
over, in agreement with our previous findings (8, 12, 14), we
could not observe elevation of serum GH and IGF-I after ad-
ministration of MR-409 for 2 wk, suggesting direct cardiac acti-
vation. In fact, subcutaneous administration of MR-409 should
increase GH levels after 15 and 30 min and last for 30–60 min
(13); thus, we cannot exclude an initial raise in GH. However,
the beneficial role of GH on cardiac function is controversial (8,
33), whereas the receptor-mediated cardioprotective effects of
GHRH and its analogs have been clearly demonstrated, in support
of a direct antihypertrophic action of MR-409. Furthermore, it
cannot be excluded that in our model of cardiac hypertrophy MR-
409 may stimulate the regeneration of cardiac stem cells, since it
has been recently demonstrated that GHRH-R agonists, including
MR-409, promote the proliferation and survival of cardiac stem
cells in vivo and in vitro (8, 12).
The effects on cardiac function in vivo were confirmed by ex
vivo experiments in isolated CMs, where MR-409 potently in-
creased inotropic and lusotropic parameters. A similar beneficial
effect on signaling and, consequently, on cardiac function has
been described for β-AR normalization induced by β-AR
blockers in HF (34). From the morphological side, we observed,
in the same treated CMs, a plasticity of the cell surface in terms
of an increment in z-groove ratio compared with untreated TAC
cells. These results recapitulated what was recently demon-
strated through AAV9.SERCA2a gene therapy for HF by our
group: that is, reappearance of z-grooves and T-tubules and β2-
AR relocalization in the reverse remodeled hearts (35).
In summary, our study demonstrates that GHRH and its an-
alog MR-409 not only counteract maladaptive hypertrophy un-
der pathological conditions, but also improve cardiac function in
a model of HF with reduced ejection fraction. These findings
have important therapeutic implications for disorders charac-
terized by cardiac hypertrophy and HF, since they establish
GHRH agonists as novel regulators of hypertrophy and strongly
support further translational testing for the treatment of HF.
Methods
Cell Lines and Reagents. H9c2 cardiac cells were cultured as described pre-
viously (7). Rat, human, mouse GHRH(1-44)-NH2, and JV-1-36 were from
Phoenix Pharmaceuticals. Synthesis and purification of MR-409 [N-Me-Tyr1,
D-Ala2, Orn12, Abu15, Orn21, Nle27, Asp28)-hGHRH(1-29)NH-CH3)] in the lab-
oratory of A.V.S. has been described previously (13).
Isolation of ARVMs. ARVMs were obtained from young adult rats (1–3 mo) by
enzymatic dissociation and cultured as described previously (7). All proce-
dures were approved by the Animal Care and Use Committee of the Uni-
versity of Turin, in accordance with the European Directive 2010/63/EU.
Generation of iPSC-CMs. iPSC-CMs were differentiated from human iPSCs
previously generated from skin fibroblasts of healthy individuals, as described
previously (36).
Cell Surface Area.ARVMswere fixedwith paraformaldehyde and stainedwith
α-actinin antibody (1:800), then with Alexa Fluor-546 antibody (1:450; Life
Technologies). Analysis was performed using an Olympus Fluoview
200 confocal head with an Ar/Kr laser (488 and 568 nm; magnification, 60×)
and area calculated using ImageJ software.
RT-PCR and Real-Time PCR. RT-PCR and real-time PCR analysis were performed
as described previously (7, 10). The primer sequences and amplification
products are described in Tables S1 and S2.
Western Blot Analysis. Western blotting was performed as described pre-
viously (10, 37).
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Fig. 4. Signaling pathways involved in the antihypertrophic effects of
GHRH in vitro. Antihypertrophic actions of GHRH include GHRH-R–
dependent activation of the AC/cAMP/PKA pathway (Left). GHRH inhibits
PE-induced signaling by blocking the α1-AR/Gq pathway and its downstream
effectors (Right). GHRH also counteracts the increase in Epac1 by PE through
activation of PKA and inhibition of Epac1-induced hypertrophic pathways
(Center). Cross-talk mechanisms between β1-AR/Gαs/Epac1 and α1-AR/Gq
signaling are shown. “+” and “−” indicate stimulatory and inhibitory effects,
respectively; interrupted lines indicate indirect effects. Abbreviations: Cn,
calcineurin; DAG, diacylglycerol; Epac1, exchange protein directly activated
by cAMP; GSK-3β, glycogen synthase kinase-3 β; HDACs, class II histone
deacetylases; IP3, inositol trisphosphate; MAPKs, mitogen-activated protein
kinases; NFAT, nuclear factor of activated T cells; PLN(Ser16) phospholamban
at serine 16; PLN(Thr17) phospholamban at threonine 17.
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Animals. All procedures were performed according to institutional guidelines
in compliance with national (D.L. N.26, 04/03/2014) and international law and
policies (new directive 2010/63/EU). The protocol was approved by the Italian
Ministry of Health. TAC or sham surgery was performed in 8-wk-old C57BL/6J
male mice as described previously (38). Fourteen days after the operation,
mice were subcutaneously injected with MR-409 (500 μg/kg/day for 14 d) or
vehicle, and killed 14 d after treatment.
In Vivo Cardiac Physiology. Transthoracic echocardiography was performed at
baseline, 14 d after the operations, and at the end of treatments in mice
anesthetized with 1% isoflurane, as described previously (39). The pressure
gradient was measured by Doppler echocardiography.
Isolation of Adult Mice CMs and Contractility. CMs were isolated from adult
male mice using standard enzymatic techniques and contractility was mea-
sured as described previously (38, 40).
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